Interestingly, the exosome-based detection of EGFR T790M in the plasma and pleural fluid of prospectively enrolled NSCLC patients after first-line TKI therapy also demonstrated greater sensitivity [179]. Here, EGFR is linked to non-small cell lung carcinoma.